Loading…
Chinese pharma holding company whose main unit, GeneScience, makes growth hormone and other biologics.
Chinese pharma holding company whose main unit, GeneScience, makes growth hormone and other biologics.
Earns most through GeneScience, whose growth-hormone injections for children are prescribed by hospital specialists, with vaccines through Baike as a second line. The listed parent is a holding company that consolidates its subsidiaries, so the strength of those units decides results.
In one line: A Chinese growth-hormone specialist wrapped in a holding company.
Moat: narrow (brand, regulatory licence, distribution). GeneScience is the dominant domestic growth-hormone brand with an established pediatric-endocrinology sales channel.
Headquarters: Changchun, China · Employees: 12,364
Size Changchun High-Tech Industry (Group) (000661.SZ) is a China Health Care company (Biotechnology) with a market value of $4.51B, the 568th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥73.77 on 6 Nov 2026.
Performance Over six months the shares fell 13.1%, against -1.2% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 18.3% over the last twelve months (peer median +11.5%); the operating margin is -1.4% (peer median -35.0%).
Valuation It trades at 30.2× forward earnings against a peer median of 37.3× (3rd cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.1 points below its cost of capital (10.0% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.5B | CN¥12.0B | CN¥13.4B | CN¥14.5B | CN¥12.6B |
| Revenue growth | — | -10% | -8% | +15% | — |
| Gross profit | CN¥8.63B | CN¥9.40B | CN¥11.1B | CN¥12.2B | CN¥10.8B |
| EBITDA | n/a | CN¥1.02B | CN¥3.73B | CN¥5.91B | CN¥5.35B |
| Net income | -CN¥424M | CN¥155M | CN¥2.58B | CN¥4.53B | CN¥4.14B |
| Free cash flow | CN¥703M | -CN¥1.40B | CN¥924M | CN¥3.01B | CN¥737M |
| Capital expenditure | CN¥1.78B | CN¥2.20B | CN¥2.18B | CN¥2.10B | CN¥2.09B |
| Total debt | CN¥2.30B | CN¥1.94B | CN¥1.56B | CN¥1.71B | CN¥1.72B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Changchun High-Tech Industry (Group) 000661.SZ | $4.51B | -13% | -18% | -1% | 30.2× | 32.2% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
| Hualan Biological Engineering 002007.SZ | $3.37B | -15% | -11% | 17% | 25.5× | 16.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000661.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.6% | +2.1% | 8th highest of 21 |
| 6-month return | -13.1% | -1.2% | 3rd lowest of 21 |
| Distance from 52-week high | -38.9% | -23.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | -18.3% | +11.5% | 5th lowest of 16 |
| Operating margin | -1.4% | -35.0% | 6th highest of 16 |
| Forward P/E | 30.2× | 37.3× | 3rd cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 32.2% | 15.8% | 2nd most demanding of 5 |
| Growth delivered (Del g) | +7.1% | +14.5% | 2nd lowest of 5 |
| Hurdle (Req g minus delivered) | +25.1 pp | +7.0 pp | most demanding of 5 |
| ROIC minus cost of capital | -8.1 pp | -11.2 pp | 6th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 30.2× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | n/a | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 40.9× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 13.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 13.7× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | n/a | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | n/a | -6.4% | -10.0% |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 69.9× | 36.7% | +26.2% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 110.0× | 28.4% | +16.4% |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |